Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: A population-based study

Journal of Alzheimer's Disease

Volumn 28, Issue 1, 2012, Pages 231-238

  Hansson, Oskar ^a,b   Stomrud, Erik ^a,b   Vanmechelen, Eugeen ^c   Östling, Svante ^d   Gustafson, Deborah R ^d   Zetterberg, Henrik ^d   Blennow, Kaj ^d   Skoog, Ingmar ^d  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c INNOGENETICS   (Belgium)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; amyloid 40; amyloid 42; biological markers; cohort studies; dementia; plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 84855759192     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111418     Document Type: Article

References (41)

1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, OBrien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimers disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
2. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
3. Zetterberg H, Blennow K, Hanse E (2010) Amyloid beta and APP as biomarkers for Alzheimers disease. Exp Gerontol 45, 23-29.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
5. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
6. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K (2007) Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78, 461-464. (Pubitemid 46662891)
7. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
8. FaganAM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349. (Pubitemid 46425688)
9. Hampel H, Shen Y, Walsh DM, Aisen P, ShawLM, Zetterberg H, Trojanowski JQ, Blennow K (2010) Biological markers of amyloid beta-related mechanisms in Alzheimers disease. Exp Neurol 223, 334-346.
10. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234. (Pubitemid 46591884)
11. Kawarabayashi T, Shoji M (2008) Plasma biomarkers of Alzheimers disease. Curr Opin Psychiatry 21, 260-267.
12. Skoog I (2004) Psychiatric epidemiology of old age: The H70 study-the NAPE lecture 2003. Acta Psychiatr Scand 109, 4-18. (Pubitemid 38161095)
13. Bengtsson C, Ahlqwist M, Andersson K, Bjorkelund C, Lissner L, Soderstrom M (1997) The Prospective Population Study of Women in Gothenburg, Sweden, 1968-69 to 1992-93. A 24-year follow-up study with special reference to participation, representativeness, and mortality. Scand J Prim Health Care 15, 214-219.
14. Steen B, Djurfeldt H (1993) The gerontological and geriatric population studies in Gothenburg, Sweden. Z Gerontol 26, 163-169. (Pubitemid 23245744)
15. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A (1993)Apopulation-based study of dementia in 85-year-olds. N Engl J Med 328, 153-158.
16. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IIIR), American Psychiatric Association, Washington D.C.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944. (Pubitemid 14076461)
18. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
19. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimers disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
20. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664-1671. (Pubitemid 351644132)
21. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM(2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660. (Pubitemid 44062411)
22. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, Schupf N, Mayeux RP (2008) Plasma ss-amyloid and cognitive decline. Arch Neurol 67, 1485-1490.
23. Abdullah L, Luis C, Paris D, Ait-ghezala G, Mouzon B, Allen E, Parrish J, Mullan MA, Ferguson S, Wood M, Crawford F, MullanM(2009) High serum Abeta and vascular risk factors in first-degree relatives of Alzheimers disease patients. Mol Med 15, 95-100.
24. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma Abeta]40 and A(beta)42 and Alzheimers disease: Relation to age, mortality, and risk. Neurology 61, 1185-1190.
25. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimers disease. Proc Natl Acad Sci U S A 105, 14052-14057.
26. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of lowplasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
27. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266.
28. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65, 256-263. (Pubitemid 351240790)
29. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H (2009) Validation of Alzheimers disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimers Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44, 579-585.
30. Seppala TT, Herukka SK, Hanninen T, Tervo S, Hallikainen M, Soininen H, Pirttila T (2010) Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81, 1123-1127.
31. Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA (2010) Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimers disease in patients with mild cognitive impairment. Neurobiol Aging 31, 539-540; author reply 541.
32. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimers disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
33. Mendez MF, Underwood KL, Zander BA, Mastri AR, Sung JH, FreyWH, 2nd (1992) Risk factors in Alzheimers disease: a clinicopathologic study. Neurology 42, 770-775.
34. Prince M, Cullen M, Mann A (1994) Risk factors for Alzheimers disease and dementia: A case-control study based on the MRC elderly hypertension trial. Neurology 44, 97-104. (Pubitemid 24029437)
35. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC (2007) Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol 66, 264-271. (Pubitemid 46559019)
36. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
37. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S (2009) No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 55, 820-825.
38. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
39. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimers disease. Alzheimers Dement 5, 18-29.
40. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, BretelerMM(2004) Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-575. (Pubitemid 38391975)
41. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29. (Pubitemid 43739586)